Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific personnel transaction rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The filing details a specific increase in the notional allocation of Ordinary share ADRs within the US Retirement Savings Plan following a re-valuation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R (1)(c).
Key Facts for Investor Verification
- Transaction Date: 2 September 2011 (Notification date: 6 September 2011).
- Individuals Involved: Dr M M Slaoui (Director/PDMR) and Dr K Slaoui (Connected Person).
- Transaction Details: Increase of 4 Ordinary share ADRs.
- Price: $41.74 per ADR.
- Context: Result of a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan.